Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs

Michele Massimino(University of Catania), Paolo Vigneri(Humanitas University)

Frontiers in Pharmacology

March 23, 2026

10.3389/fphar.2026.1780054

Cited by 0

Related Papers

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer

|Critical Reviews in Oncology/Hematology|2025|5

REThinking the role of the RET oncogene in breast cancer

|Frontiers in Oncology|2024|3

Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.

|Journal of Clinical Oncology|2025|1

Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis

|JNCI Cancer Spectrum|2025|1

Abstract P1-10-14: Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive(HR+)/HER2-negative(-) metastatic breast cancer (mBC)

|Clinical Cancer Research|2025|0